Frequently Asked Questions
Answers to common questions about the triple-agonist peptide.
- What makes Retatrutide different from Semaglutide or Tirzepatide?
Semaglutide is a single agonist (GLP-1), Tirzepatide is a dual agonist (GLP-1 and GIP), and Retatrutide is a triple agonist targeting GLP-1, GIP, and Glucagon receptors. The addition of the glucagon receptor theoretically increases resting energy expenditure.
- Is Retatrutide FDA approved?
No. Retatrutide is currently an investigational drug undergoing Phase 3 clinical trials. It has not been approved for human consumption by the FDA or any other regulatory body.
- How much weight loss was observed in Phase 2 trials?
In Phase 2 clinical trials, participants on the highest dose (12 mg) experienced a mean weight reduction of approximately 24.2% over 48 weeks.
- What is the standard dosing protocol?
Clinical protocols utilize a 4-week step-up escalation to mitigate side effects. A common research protocol starts at 2mg weekly for 4 weeks, escalating to 4mg for 4 weeks, and continuing to step up based on tolerability.
- What are the most common side effects?
The most commonly reported adverse events in clinical trials were gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These effects were generally dose-dependent and transient.